ACM
CEREW

Altium Capital Management’s Cerevel Therapeutics Holdings, Inc. Warrant CEREW Stock Holding History

Altium Capital Management’s Portfolio CEREW Stock Details CEREW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-64,666
Closed -$365K – 150
2020
Q4 		$365K Buy
+64,666
New +$261K 0.14% 86

Other funds holding CEREW

HCM
Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
GL
Governors Lane New York $1.56B AUM 30.42% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

Altium Capital Management's CEREW Position: Q1 2021 in Review

Altium Capital Management sold out of Cerevel Therapeutics Holdings, Inc. Warrant (CEREW) in Q1 2021, closing a stake of 64,666 shares — an estimated $365K sold.

Altium Capital Management first reported a position in CEREW in Q4 2020 and held it in 1 quarter. The position peaked at $365K in Q4 2020. 29 funds tracked by Wall St. Rank hold CEREW as of Q1 2021.

  • Altium Capital Management reported no remaining Cerevel Therapeutics Holdings, Inc. Warrant position as of Q1 2021 after selling out during the quarter.
  • Altium Capital Management sold 64,666 Cerevel Therapeutics Holdings, Inc. Warrant shares in Q1 2021, an estimated $365K.
  • Altium Capital Management first reported a position in Cerevel Therapeutics Holdings, Inc. Warrant in Q4 2020 and held it in 1 quarter.
  • Altium Capital Management's Cerevel Therapeutics Holdings, Inc. Warrant position peaked at $365K in Q4 2020.
  • 29 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Warrant as of Q1 2021.

Based on Altium Capital Management's 13F filing for Q1 2021, filed 6 May 2021.